Edwards Lifesciences Corp | 2013 | FY | 3


 

 

 
  Years Ended December 31,  
 
  2013   2012   2011  
 
  (in millions)
 

Settlements and litigation

  $ (83.6 ) $ —   $ 3.3  

Realignment expenses

    10.4     9.0     5.5  

IPR&D impairment

    5.9     —     —  

Licensing of intellectual property

    —     7.0     —  

European receivables reserve

    —     —     12.8  
               
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Total special (gains) charges

  $ (67.3 ) $ 16.0   $ 21.6  
               
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
               

us-gaap:ScheduleOfUnusualOrInfrequentItemsTextBlock